Journal articles: 'Cancer – Adjuvant treatment'

1

Rubens, R. D. "Breast cancer: Adjuvant treatment." European Journal of Cancer 28, no. 2-3 (February 1992): 620–22. http://dx.doi.org/10.1016/s0959-8049(05)80111-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

McClellan, M. B. "Adjuvant Breast Cancer Treatment." JAMA: The Journal of the American Medical Association 288, no. 17 (November 6, 2002): 2112—a—2112. http://dx.doi.org/10.1001/jama.288.17.2112-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McClellan, Mark B. "Adjuvant Breast Cancer Treatment." JAMA 288, no. 17 (November 6, 2002): 2112. http://dx.doi.org/10.1001/jama.288.17.2112-jfd20011-2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wolpin, B. M., J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer. "Adjuvant Treatment of Colorectal Cancer." CA: A Cancer Journal for Clinicians 57, no. 3 (May 1, 2007): 168–85. http://dx.doi.org/10.3322/canjclin.57.3.168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Agboola, Olu. "Adjuvant treatment in gastric cancer." Cancer Treatment Reviews 20, no. 3 (July 1994): 217–40. http://dx.doi.org/10.1016/0305-7372(94)90001-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Neoptolemos, John P. "Adjuvant treatment of pancreatic cancer." European Journal of Cancer 47 (September 2011): S378—S380. http://dx.doi.org/10.1016/s0959-8049(11)70210-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wils, J. A. "Adjuvant treatment of colorectal cancer." Acta chirurgica Iugoslavica 49, no. 2 (2002): 15–18. http://dx.doi.org/10.2298/aci0202015w.

Full text

Abstract:

Colorectal cancer is a leading cause of morbidity and mortality, with approximately 300,000 new cases and 200,000 related deaths in Europe and the USA each year. Adjuvant treatment of colorectal cancer is now widely accepted and can reduce mortality with approximately 10%. This can be considered as one of the major achievements in oncology from the past decade. Current results will be discussed and strategies for the future will be outlined, including on-going or planned large-scale trials with new drugs and approaches.

APA, Harvard, Vancouver, ISO, and other styles

8

Klaiber, Ulla, Thilo Hackert, and John P. Neoptolemos. "Adjuvant treatment for pancreatic cancer." Translational Gastroenterology and Hepatology 4 (April 2019): 27. http://dx.doi.org/10.21037/tgh.2019.04.04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Midgley, R. S., and D. J. Kerr. "Adjuvant treatment of colorectal cancer." Cancer Treatment Reviews 23, no. 3 (May 1997): 135–52. http://dx.doi.org/10.1016/s0305-7372(97)90035-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Passant, Helen, and Annabel Borley. "Adjuvant treatment for breast cancer." Surgery (Oxford) 28, no. 3 (March 2010): 140–43. http://dx.doi.org/10.1016/j.mpsur.2009.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Passant, Helen, and Annabel Borley. "Adjuvant treatment for breast cancer." Surgery (Oxford) 31, no. 1 (January 2013): 37–40. http://dx.doi.org/10.1016/j.mpsur.2012.10.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Flatley, Michael J., and David J. Dodwell. "Adjuvant treatment for breast cancer." Surgery (Oxford) 34, no. 1 (January 2016): 43–46. http://dx.doi.org/10.1016/j.mpsur.2015.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Flatley, Michael J., and David J. Dodwell. "Adjuvant treatment for breast cancer." Surgery (Oxford) 37, no. 3 (March 2019): 176–80. http://dx.doi.org/10.1016/j.mpsur.2019.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Lise, Mario, Donate Nitti, Alberto Marchet, and Adriano Fornasiero. "Adjuvant treatment for gastric cancer." Anti-Cancer Drugs 2, no. 5 (October 1991): 433–46. http://dx.doi.org/10.1097/00001813-199110000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Bleiberg, Harry. "Adjuvant treatment of colon cancer." Current Opinion in Oncology 17, no. 4 (July 2005): 381–85. http://dx.doi.org/10.1097/01.cco.0000166648.92674.4c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Conroy, Thierry, and Michel Ducreux. "Adjuvant treatment of pancreatic cancer." Current Opinion in Oncology 31, no. 4 (July 2019): 346–53. http://dx.doi.org/10.1097/cco.0000000000000546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Emons, Günter, and Dirk Vordermark. "Adjuvant treatment for endometrial cancer." Current Opinion in Oncology 31, no. 5 (September 2019): 404–10. http://dx.doi.org/10.1097/cco.0000000000000558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Saltz, MD, Leonard B., and David P. Kelsen, MD. "ADJUVANT TREATMENT OF COLORECTAL CANCER." Annual Review of Medicine 48, no. 1 (February 1997): 191–202. http://dx.doi.org/10.1146/annurev.med.48.1.191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Beretta, Giordano D., L. Milesi, M. A. Pessi, S. Mosconi, and R. Labianca. "Adjuvant treatment of colorectal cancer." Surgical Oncology 13, no. 2-3 (August 2004): 63–73. http://dx.doi.org/10.1016/j.suronc.2004.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Taal, B. G., H. van Tinteren, and L. van t Veer. "Adjuvant treatment in colorectal cancer." British Journal of Cancer 86, no. 9 (May 2002): 1525–26. http://dx.doi.org/10.1038/sj.bjc.6600280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Slevin, M. L. "Adjuvant treatment for colorectal cancer." BMJ 312, no. 7028 (February 17, 1996): 392–93. http://dx.doi.org/10.1136/bmj.312.7028.392.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Aithal, G., and A. Tanner. "Adjuvant treatment for colorectal cancer." BMJ 312, no. 7043 (June 1, 1996): 1417. http://dx.doi.org/10.1136/bmj.312.7043.1417.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Macdonald, John S., and Sandra F. Schnall. "Adjuvant treatment of gastric cancer." World Journal of Surgery 19, no. 2 (1995): 221–25. http://dx.doi.org/10.1007/bf00308630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Plowman, P. N., W. H. Allum, TrevorJ Powles, IanE Smith, Barnett Zumoff, A. Y. Rostom, A. R. Gershuny, HelenS Kaplan, and Heather Goodare. "Adjuvant treatment in breast cancer." Lancet 339, no. 8790 (February 1992): 423–24. http://dx.doi.org/10.1016/0140-6736(92)90106-d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gelber, R. D. "Breast cancer and adjuvant treatment." Biomedicine & Pharmacotherapy 48, no. 8-9 (January 1994): 409. http://dx.doi.org/10.1016/0753-3322(94)90067-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Metzger, Urs F., Bimal C. Ghosh, and Daniel L. Kisner. "Adjuvant treatment of colorectal cancer." Cancer Chemotherapy and Pharmacology 14, no. 1 (1985): 1–8. http://dx.doi.org/10.1007/bf00552715.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Taylor, I. "Adjuvant treatment of colon cancer." European Journal of Cancer 30, no. 5 (January 1994): 579–80. http://dx.doi.org/10.1016/0959-8049(94)90522-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Aoki, Yoichi, Hiroyuki Kanao, Xipeng Wang, Mayu Yunokawa, Kohei Omatsu, Atsushi Fusegi, and Nobuhiro Takeshima. "Adjuvant treatment of endometrial cancer today." Japanese Journal of Clinical Oncology 50, no. 7 (May 28, 2020): 753–65. http://dx.doi.org/10.1093/jjco/hyaa071.

Full text

Abstract:

Abstract Endometrial cancer frequently occurs in post-menopausal women, and the endometrium is a well-known site of cancer affecting women. Endometrial cancer is found with genital bleeding and often at an early stage. However, there are some risks of recurrence after hysterectomy. As a medical treatment after the diagnosis of endometrial cancer, appropriate adjuvant therapy is considered to lead to a decrease in the rate of recurrence and improvement of prognosis according to the determination of the cancer stage from the surgical and histopathological results. In this review, we describe post-operative adjuvant therapy administered for endometrial cancer and advanced disease, focusing on chemotherapy, radiation therapy and the combination of both. These treatments are divided according to the risk of recurrence as based primarily on the reported evidence.

APA, Harvard, Vancouver, ISO, and other styles

29

Chua, Yu Jo, and David Cunningham. "Adjuvant Treatment for Resectable Pancreatic Cancer." Journal of Clinical Oncology 23, no. 20 (July 10, 2005): 4532–37. http://dx.doi.org/10.1200/jco.2005.17.954.

Full text

Abstract:

There are relatively few randomized studies of adjuvant chemoradiotherapy and chemotherapy in patients with resected pancreatic adenocarcinoma. The European Study Group for Pancreatic Cancer 1 (ESPAC1) trial is the largest study of adjuvant treatment to date. The results of ESPAC1 are discussed in the context of other evidence from previous randomized studies, which have also been combined in a meta-analysis. Overall, the existing data show a clear benefit for postoperative adjuvant chemotherapy, which has not been demonstrated for adjuvant chemoradiotherapy. The subgroup of patients with resection margin positive disease did seem to benefit less from adjuvant chemotherapy, and showed a trend towards improved survival with chemoradiotherapy. Adjuvant chemoradiotherapy should be evaluated further in this latter group of patients. The optimal chemotherapy regimen for use as adjuvant treatment is the subject of ongoing trials. Other strategies which should be explored include neoadjuvant treatment and the incorporation of novel targeted agents into management.

APA, Harvard, Vancouver, ISO, and other styles

30

Miller, Elizabeth, Hee Jin Lee, Amriti Lulla, Liz Hernandez, Prashanth Gokare, and Bora Lim. "Current treatment of early breast cancer: adjuvant and neoadjuvant therapy." F1000Research 3 (August 19, 2014): 198. http://dx.doi.org/10.12688/f1000research.4340.1.

Full text

Abstract:

Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer statistics calculated by the International Agency for Research on Cancer (IARC) revealed that 1,677,000 women were diagnosed with breast cancer in 2012 and 577,000 died. The TNM classification of malignant tumor (TNM) is the most commonly used staging system for breast cancer. Breast cancer is a group of very heterogeneous diseases. The molecular subtype of breast cancer carries important predictive and prognostic values, and thus has been incorporated in the basic initial process of breast cancer assessment/diagnosis. Molecular subtypes of breast cancers are divided into human epidermal growth factor receptor 2 positive (HER2 +), hormone receptor positive (estrogen or progesterone +), both positive, and triple negative breast cancer. By virtue of early detection via mammogram, the majority of breast cancers in developed parts of world are diagnosed in the early stage of the disease. Early stage breast cancers can be completely resected by surgery. Over time however, the disease may come back even after complete resection, which has prompted the development of an adjuvant therapy. Surgery followed by adjuvant treatment has been the gold standard for breast cancer treatment for a long time. More recently, neoadjuvant treatment has been recognized as an important strategy in biomarker and target evaluation. It is clinically indicated for patients with large tumor size, high nodal involvement, an inflammatory component, or for those wish to preserve remnant breast tissue. Here we review the most up to date conventional and developing treatments for different subtypes of early stage breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

31

Taghizadeh, Hossein, and Gerald W. Prager. "Personalized Adjuvant Treatment of Colon Cancer." Visceral Medicine 36, no. 5 (2020): 397–406. http://dx.doi.org/10.1159/000508175.

Full text

Abstract:

Introduction: Colon cancer (CC) is one of the most frequent malignant diseases. Adjuvant chemotherapy is of utmost importance in the management of localized disease. With the emergence of precision medicine, treatment approaches are becoming increasingly personalized and complex. This review contributes to a broader understanding of the role and relevance of personalized adjuvant treatment strategies in colon carcinoma, and summarizes the current status in this disease entity. Methods: We searched the websites ClinicalTrials.gov, PubMed, and ASCO (American Society of Medical Oncology) Meeting Library for clinical trials and retrospective analyses in the field of adjuvant treatment of CC with special attention to personalized approaches. Results: Various factors, including gender, age, sidedness, stage, dMMR/MSI-H, mutations, molecular profile, CMS, immunoscore, minimal residual disease, type of adjuvant therapy, therapy duration, and the patient’s wish play an important role in the adjuvant setting of CC and should be considered in treatment decision making. Conclusion: Future molecular profiling ideally assessed and monitored by liquid biopsy might personalize decision making even more in the adjuvant setting of CC patients. Further research and clinical trials are needed to clarify relevant questions and to highlight important clinical aspects.

APA, Harvard, Vancouver, ISO, and other styles

32

Akerley, Wallace L. "Contemporary Adjuvant Treatment of Breast Cancer." Surgical Oncology Clinics of North America 4, no. 4 (October 1995): 685–99. http://dx.doi.org/10.1016/s1055-3207(18)30424-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Palloni, Andrea, Giorgio Frega, Stefania De Lorenzo, Alessandro Rizzo, Francesca Abbati, Marzia Deserti, Simona Tavolari, and Giovanni Brandi. "Adjuvant treatment in biliary tract cancer." Translational Cancer Research 8, S3 (April 2019): S289—S296. http://dx.doi.org/10.21037/tcr.2018.08.17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Neoptolemos, J. "71 Adjuvant treatment for pancreatic cancer." European Journal of Cancer Supplements 1, no. 5 (September 2003): S26. http://dx.doi.org/10.1016/s1359-6349(03)90105-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dal Lago, Lissandra, Chantal Bernard-Marty, and Martine J. Piccart. "Adjuvant treatment of early breast cancer." European Journal of Cancer Supplements 3, no. 3 (October 2005): 149–66. http://dx.doi.org/10.1016/s1359-6349(05)80272-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Minsky, Bruce D. "The adjuvant treatment of esophageal cancer." Seminars in Radiation Oncology 4, no. 3 (July 1994): 165–69. http://dx.doi.org/10.1016/s1053-4296(05)80064-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Smith, I. "Adjuvant treatment for early breast cancer." Annals of Oncology 16 (June 2005): ii182—ii187. http://dx.doi.org/10.1093/annonc/mdi709.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Reizenstein, Peter. "ADJUVANT SYSTEMIC TREATMENT FOR BREAST CANCER." Lancet 333, no. 8640 (April 1989): 728. http://dx.doi.org/10.1016/s0140-6736(89)92244-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Knauer, Michael, and Beat Thürlimann. "Adjuvant Bisphosphonates in Breast Cancer Treatment." Breast Care 9, no. 5 (2014): 10. http://dx.doi.org/10.1159/000368760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Galloway, D. J., A. M. Cohen, B. Shank, and M. A. Friedman. "Adjuvant multimodality treatment of rectal cancer." British Journal of Surgery 76, no. 5 (May 1989): 440–47. http://dx.doi.org/10.1002/bjs.1800760507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

NEWMAN, E., D. SIMEONE, and M. MULHOLLAND. "Adjuvant Treatment Strategies for Pancreatic Cancer." Journal of Gastrointestinal Surgery 10, no. 6 (June 2006): 916–26. http://dx.doi.org/10.1016/j.gassur.2005.10.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Eifel, Patricia J. "Intermediate-risk endometrial cancer—adjuvant treatment." Nature Reviews Clinical Oncology 7, no. 10 (September 29, 2010): 553–54. http://dx.doi.org/10.1038/nrclinonc.2010.138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chhatwani, L., E. Cabebe, and H. A. Wakelee. "Adjuvant Treatment of Resected Lung Cancer." Proceedings of the American Thoracic Society 6, no. 2 (April 15, 2009): 194–200. http://dx.doi.org/10.1513/pats.200807-068lc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Relman, Arnold S. "Adjuvant Treatment of Early Breast Cancer." New England Journal of Medicine 320, no. 8 (February 23, 1989): 525. http://dx.doi.org/10.1056/nejm198902233200810.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Schlag, P. "Adjuvant treatment in colo-rectal cancer." European Journal of Cancer 29 (January 1993): S9. http://dx.doi.org/10.1016/0959-8049(93)90651-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Goldhirsch, A. "Adjuvant treatment in operable breast cancer." Journal of Steroid Biochemistry 23, no. 6 (December 1985): 1155–60. http://dx.doi.org/10.1016/0022-4731(85)90036-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Holmes, E. Carmack. "Adjuvant treatment in resected lung cancer." Seminars in Surgical Oncology 6, no. 5 (1990): 263–67. http://dx.doi.org/10.1002/ssu.2980060507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Leighl, Natasha, Melina Gattellari, Phyllis Butow, Richard Brown, and Martin H. N. Tattersall. "Discussing Adjuvant Cancer Therapy." Journal of Clinical Oncology 19, no. 6 (March 15, 2001): 1768–78. http://dx.doi.org/10.1200/jco.2001.19.6.1768.

Full text

Abstract:

PURPOSE: To document the adequacy of patient information in oncology consultations concerning adjuvant therapy and explore predictors of physician communication patterns, treatment decisions, patient information recall, and satisfaction. PATIENTS AND METHODS: Retrospective analysis of audiotapes and verbatim transcripts of 101 initial adjuvant therapy consultations with medical and radiation oncologists was undertaken. Content analysis, data on communication patterns, treatment decisions, patient anxiety, satisfaction, and information recall were collected. Predictors of physician communication, treatment decisions, recall, and satisfaction with the consultation were identified. RESULTS: The majority of patients were well informed of their prognosis, benefits and risks of therapy, and alternative management options. Only half were asked about preferences for information or decision-making involvement. Predictors of information detail given include patient sex, age, occupation, and education. Radiation and medical oncologists express prognosis and treatment benefit using similar phrases. When offered the chance to delay decision-making, most patients do so (P < .01). Final treatment decisions appear to be influenced by the presentation of choice in treatment options by the oncologist and whether the treatment decision was made during the initial consultation (P < .01). Information recall was not influenced by communication factors. Patients receiving less detailed information had slightly higher satisfaction with the consultation (P = .03). More anxious patients tended to be less satisfied (P = .07). CONCLUSION: The optimal way to discuss adjuvant therapy is undefined. More emphasis can be placed on soliciting patient preferences for information and decision-making involvement and tailoring both to the needs of the individual patient. Providing choice in treatment and delaying decision-making may affect the patient’s treatment decision.

APA, Harvard, Vancouver, ISO, and other styles

49

Osorio, Marlon, Estefanía Martinez, Tonny Naranjo, and Cristina Castro. "Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review." Molecules 25, no. 10 (May 12, 2020): 2270. http://dx.doi.org/10.3390/molecules25102270.

Full text

Abstract:

Colorectal cancer (CRC) is the type with the second highest morbidity. Recently, a great number of bioactive compounds and encapsulation techniques have been developed. Thus, this paper aims to review the drug delivery strategies for chemotherapy adjuvant treatments for CRC, including an initial scientific-technological analysis of the papers and patents related to cancer, CRC, and adjuvant treatments. For 2018, a total of 167,366 cancer-related papers and 306,240 patents were found. Adjuvant treatments represented 39.3% of the total CRC patents, indicating the importance of adjuvants in the prognosis of patients. Chemotherapy adjuvants can be divided into two groups, natural and synthetic (5-fluorouracil and derivatives). Both groups can be encapsulated using polymers. Polymer-based drug delivery systems can be classified according to polymer nature. From those, anionic polymers have garnered the most attention, because they are pH responsive. The use of polymers tailors the desorption profile, improving drug bioavailability and enhancing the local treatment of CRC via oral administration. Finally, it can be concluded that antioxidants are emerging compounds that can complement today’s chemotherapy treatments. In the long term, encapsulated antioxidants will replace synthetic drugs and will play an important role in curing CRC.

APA, Harvard, Vancouver, ISO, and other styles

50

Schultz-Lampel, Daniela, and Alexander Lampel. "Neo-adjuvant and adjuvant treatment of locally invasive bladder cancer." Current Opinion in Urology 9, no. 5 (September 1999): 419–24. http://dx.doi.org/10.1097/00042307-199909000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Cancer – Adjuvant treatment'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles